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Abstract 
Introduction: To establish a prognostic model for predicting 14-day mortality in ICU 
patients with severe sepsis overall and according to place of infection acquisition and to sepsis 
episode number. 
Methods: In this prospective multicentre observational study on a multicentre database 
(OUTCOMEREA) including data from 12 ICUs, 2268 patients with 2737 episodes of severe 
sepsis were randomly divided into a training cohort (n=1458) and a validation cohort (n=810). 
Up to four consecutive severe sepsis episodes per patient occurring within the first 28 ICU 
days were included. We developed a prognostic model for predicting death within 14 days 
after each episode, based on patient data available at sepsis onset. 
Results: Independent predictors of death were logistic organ dysfunction (OR, 1.22 per point, 
p<10-4), septic shock (OR, 1.40; p=0.01), rank of severe sepsis episode (1 reference, 2: OR, 
1.26; p=0.10 [greater than or equal to]3: OR, 2.64 ;10-3), multiple sources of infection (OR; 
1.45, p=0.03), simplified acute physiology score II (OR, 1.02 per point; p<10-4), McCabe 
score ([greater than or equal to]2)(OR, 1.96; p<10-4), and number of chronic co-morbidities 
(1: OR, 1.75; p=10-3, [greater than or equal to]2: OR, 2.24, p= 10-3). Validity of the model 
was good in whole cohorts (AUC-ROC, 0.76; 95%CI [0.74; 0.79] and HL Chi-square: 15.3 
(p=0.06) for all episodes pooled). 
Conclusions: In ICU patients, a prognostic model based on a few easily obtained variables is 
effective in predicting death within 14 days after the first to fourth episode of severe sepsis 
complicating community-, hospital-, or ICU-acquired infection.   
 
Introduction: 
 
 Severe sepsis remains a leading cause of death in industrialized countries, and the 
number of deaths caused by sepsis is increasing despite improved survival rates [1, 2]. Apart 
from measures directed to the infectious cause (antibiotics and surgery), the treatment remains 
chiefly supportive despite many randomised controlled trials [3, 4]. Sepsis is a syndrome, not 
a disease; and many factors explain the variability of outcomes, such as differences in 
infection sites, causative pathogens, and time and location of infection onset (community, 
hospital, or ICU) [1]. This heterogeneity explains that no reliable measures of disease activity 
have been identified. Attempts to select uniform populations often used ill-defined non-
inclusion criteria such as moribund status.  
 Despite the current tendency to focus on mortality rates after 1 year or longer, which 
are highly relevant to cost-effectiveness issues, short-term mortality may be a more 
appropriate outcome for determining whether new treatments correct the acute effects of 
severe sepsis, since many patients who recover from severe sepsis die later on from pre-
existing chronic illnesses. Moreover, outcomes and risk factors of patients with severe sepsis 
vary considerably with the number of episodes and with the time and place of acquisition 
(community, hospital, or ICU). 
 The objective of this study was to design a prognostic model for predicting death 
within 14 days of severe sepsis onset at any time during the first 28 days of the ICU stay. The 
model was to be based on variables collected at admission and on the day the sepsis episode 
was diagnosed. Up to four sepsis episodes per patient were included. We evaluated the 
performance of our model separately in subgroups defined based on the place of infection 
acquisition. We compared our model to other, widely used scores. Our model may prove 
useful for designing future studies.  
Methods and materials: 
Data Source  
We conducted a prospective observational study using data entered into a multicentre 
database (OUTCOMEREA) from November 1996 to April 2007. The database, fed by 12 
French ICUs, contains data on admission features and diagnosis, daily disease severity, 
iatrogenic events, nosocomial infections, and vital status. Data for a random sample of at least 
50 patients older than 16 years and having ICU stays longer than 24 hours were consecutively 
entered into the database each year. Each participating ICU chose to perform random 
sampling by taking either consecutive admissions to selected ICU beds throughout the year or 
consecutive admissions to all ICU beds over a single month. The contact physicians for the 
database in the participating ICUs, who are listed in the appendix, are accredited according to 
French law [5]. 
Ethical Issues 
According to French law, this study did not require patient consent, as it involved 
research on a database. The study was approved by the institutional review board of the 
Centres d’Investigation Rhône-Alpes-Auvergne. 
Data collection  
Data were collected daily by senior physicians in the participating ICUs. For each 
patient, the data were entered into an electronic case-report form using VIGIREA and 
RHEA data-capture software (OUTCOMEREATM, Rosny-sous-Bois, France), and all case-
report forms were then entered into the OUTCOMEREA data warehouse. All codes and 
definitions were established prior to study initiation. The following information was recorded 
for each patient: age and sex, admission category (medical, scheduled surgery, or unscheduled 
surgery), origin (home, ward, or emergency room), and McCabe score [6]. Based on 
previously reported reproducibility data, the McCabe score was transformed into a dummy 
variable, i.e., “death expected within 5 years, yes or no” [7]. Severity of illness was evaluated 
on the first ICU day using the Simplified Acute Physiology Score (SAPS II) [8], Logistic 
Organ Dysfunction (LOD) score [9], Mortality Probability models II0 score (MPM0 II score) 
[10, 11], and Acute Physiologic and Chronic Health Evaluation (APACHE) II score [12]. 
Knaus scale definitions were used to record pre-existing chronic organ failures including 
respiratory, cardiac, hepatic, renal, and immune system failures [12]. Patients were followed 
until the end of the hospital stay in order to record the vital status 14 days after sepsis onset. 
For the model, we computed SAPS II and LOD scores based on the data immediately 
available on admission or on the day (up to 24 hours) before the diagnosis of each episode of 
sepsis. 
Quality of the database 
The data-capture software automatically conducted multiple checks for internal 
consistency of most of the variables at entry in the database. Queries generated by these 
checks were resolved with the source ICU before incorporation of the new data into the 
database. At each participating ICU, data quality was controlled by having a senior physician 
from another participating ICU check a 2% random sample of the study data.  
Study Population  
Because diagnostic coding has been found unreliable [13], we used parameters collected 
by our data-capture software to select patients with severe sepsis, defined as systemic 
inflammatory response syndrome (SIRS) combined with an infectious episode and 
dysfunction of at least one organ, occurring at or within 28 days after admission to the ICU. 
We excluded patients with treatment-limitation decisions taken before or on the day of the 
diagnosis of severe sepsis. At least two of the following criteria were required for the 
diagnosis of SIRS: core temperature ≥38°C or ≤36°C, heart rate ≥90 beats/min, respiratory 
rate ≥20 breaths/min, PCO2 ≤32 mm Hg or use of mechanical ventilation, and peripheral 
leukocyte count ≥12,000/mm3 or ≤4000/mm3. Organ dysfunction was defined as follows: 
cardiovascular system failure was a need for vasoactive and/or inotropic drugs, and/or systolic 
blood pressure <90 mm Hg, and/or a drop in systolic blood pressure >40 mm Hg from 
baseline; renal dysfunction was urinary output ≤700 ml/d in a patient not previously 
undergoing haemodialysis for chronic renal failure; respiratory dysfunction was PaO2 <70 
mm Hg or mechanical ventilation or a PaO2/FiO2 ratio of ≤250 (or ≤200 in patients with 
pneumonia); thrombocytopenia was a platelet count <80,000/mm3, and elevated plasma 
lactate was a lactate level ≥3 mmol/L. Severe sepsis was defined as sepsis associated with at 
least one organ dysfunction as described above, and septic shock was defined as sepsis-
induced hypotension persisting despite adequate fluid resuscitation together with organ 
dysfunction; thus, patients receiving inotropic or vasoactive agents who had organ 
dysfunction but who were no longer hypotensive were classified as having septic shock [14]. 
Lengths of ICU and hospital stays were computed starting at ICU admission. 
The presence or absence of infection was documented according to the standard 
definitions developed by the Centers for Disease Control [15]; in addition, quantitative 
cultures of specimens obtained by bronchoalveolar lavage, protected specimen brush, 
protected plugged catheter, or tracheal aspiration were required to diagnose ventilator-
associated pneumonia [16]. Community-acquired infection was defined as infection 
manifesting before or within 48 hours after hospital admission. Hospital-acquired infection 
was infection manifesting at least 48 hours after hospital admission but before ICU admission. 
ICU-acquired infection was diagnosed at least 48 hours after ICU admission. Infection sites 
were categorized as follows: pneumonia, peritonitis, urinary tract infection, exacerbation of 
chronic obstructive pulmonary disease, primary bacteraemia (excluding untreated 
Staphylococcus epidermidis bacteraemia), miscellaneous sites (mediastinitis, prostatitis, 
osteomyelitis, and others), and multiple sites. Early effective antibiotic therapy was defined as 
effectiveness on the causative agent of at least one of the empirically selected antibiotics on 
the day of the diagnosis of an episode of severe sepsis. Relapse/recurrence was defined as a 
new episode of severe sepsis with the same microorganism and the same infected organ. New 
episodes of severe sepsis involving different microorganisms or different organs from the 
previous episode were classified as separate episodes [17]. 
Outcome variable of interest 
The outcome variable of interest was death within 14 days after the diagnosis of an 
episode of severe sepsis (up to four) acquired in the community, hospital, or ICU. 
We then compared the accuracy of these models to the main usual ones (SAPS II and 
APACHE II scores, and MPM II0) 
Statistical Analysis 
Our main objective was to develop a patient-based prognostic model that predicted 
death within 14 days after the diagnosis of the first, second, third, or fourth episode of severe 
sepsis present within 28 days after ICU admission. We randomly allocated two-thirds of the 
study patients to the training cohort and the remaining third to the validation cohort. As up to 
four episodes of severe sepsis per patient were included, we conducted a cluster analysis, in 
which each cluster was composed of one patient with one to four sepsis episodes.  
Results were expressed as numbers (percentages) for categorical variables and as 
medians (quartiles) for continuous variables. Qualitative variables were compared using the 
chi-square or Fisher exact test and continuous variables using the Wilcoxon or Kruskal-Wallis 
test. A correlation exists between the 14-day outcomes of two consecutive episodes of severe 
sepsis occurring in the same patient. Consequently, the relationship between early death and 
the study variables was evaluated using generalized estimating equations [18], which are well 
suited to the analysis of correlated data. We used a logit link function, because the distribution 
of the outcome variable (14-day mortality) was binary. Correlations between multiple 
episodes of severe sepsis occurring in the same patient were estimated using Pearson residuals 
and parameters, according to the maximum likelihood method. We assumed an exchangeable-
structure correlation matrix for the data within each cluster. The number of the sepsis episode 
and the time from admission to the severe sepsis episode were introduced successively into 
the global model, and the final model that minimized the Akaike information criterion was 
retained. 
Variables associated with early death at the 0.2 level by univariate analysis were 
introduced in the multivariate model and subsequently selected in order to improve model 
deviance. The assumption that quantitative variables were linear in the logit was checked 
using cubic polynomials and graphical methods. In the absence of log-linearity, continuous 
variables were transformed into qualitative variables according to the slope of the cubic 
polynomial functions and to the distribution of the variables. A pooled test of clinically 
relevant two-way interactions was performed on the final model, and correlations between 
selected variables were verified. We checked for potential co-linearity of the variables 
included in the final model. R values of less than 0.2 were considered acceptable. 
Our primary assessment of model performance was goodness-of-fit as evaluated by 
the Hosmer-Lemeshow statistic and by calibration curves. Lower Hosmer-Lemeshow values 
and higher p values (>0.05) indicate better fit. We also assessed discrimination (i.e., the 
ability of the model to separate survivors and non-survivors) using the area under the curve 
(AUC) of the receiver-operating characteristics (ROC) curve. AUC values greater than 0.80 
indicate good discrimination.  
The quality of our model was tested separately in community-acquired, hospital-
acquired, and ICU-acquired sepsis. Then, the final model was evaluated in the validation 
cohort and compared to other models (SAPS II scores, APACHE II scores and MPM II0 
score) using the method of Hanley and McNeil to compare ROC-AUC values [19]. Analyses 
were computed using the SAS 9.1.3 package (SAS Institute, Cary, NC), R, and Medcalc 5.00 
(Medcalc, Ghent, Belgium). 
Results: 
Among the 7719 patients in the OUTCOMEREA® base, 2268 experienced 2737 
episodes of severe sepsis, including 674 patients who had 793 episodes of septic shock. Of the 
2268 patients, 1458 patients with 1716 episodes of severe sepsis were included in the training 
cohort and 810 patients with 1021 episodes of severe sepsis were included in the validation 
cohort (Figure 1), using a 2:1 randomisation procedure. Characteristics at ICU admission and 
on the day of severe sepsis onset in 14-day survivors and non-survivors are shown in Tables 1 
and 2, respectively. Factors that were significantly associated with early death included worse 
SAPS II and LOD scores at ICU admission, septic shock (e.g. requiring either inotropic 
therapy or vasoactive agent support), multiple organ failure (which showed the strongest 
association), and co-morbidities (immunodeficiency, chronic heart failure, chronic hepatic 
failure, acute respiratory failure, and acute heart failure). On the day of the diagnosis of severe 
sepsis (Table 2), factors significantly associated with early death included the use of invasive 
procedures and a need for vasoactive agents and/or inotropic support. Escherichia coli, 
Pseudomonas spp., methicillin-resistant Staphylococcus aureus, Candida spp., bacteraemia, 
and multiple sources of infection were also associated with early death in the univariate 
analysis.  
We determined the best generalized linear model, that is, the model comprising 
variables that were both readily available and independently associated with early death 
(Table 3). Among variables collected on the day of diagnosis of severe sepsis, four were 
associated with an increased risk of early death: worse LOD score, vasoactive and/or 
inotropic therapy (e.g., septic shock), second episode of severe sepsis compared to the first, 
and third or fourth episode of sepsis compared to the first. Among infection characteristics 
entered into the model, only multiple sources of infection significantly increased the risk of 
early death. Interestingly, the nature of the causative micro-organism was not an independent 
predictor of death. Among variables collected at ICU admission, the following significantly 
predicted death within 14 days of a sepsis episode: worse SAPS II score, presence of a fatal 
underlying disease yielding a McCabe score of 2 or 3, presence of one chronic illness, and 
presence of two or more chronic illnesses. Corticosteroid therapy did not predict early death, 
even when interactions with septic shock were tested (OR=0.99 [0.66-1.49], p=0.96), and 
therefore was not included in our model. Absence of early effective antibiotic therapy was 
associated with death (OR=0.69 [0.53-0.91], p=0.01) but was not introduced in the model 
because this information was not available on the day of severe sepsis. 
Despite the risk of co-linearity, we considered that LOD on the first day of sepsis and 
SAPS II at admission could be used in the same model. First, when sepsis was acquired in the 
ICU, the variables shared by these two scores were not recorded at the same time. Second, 
using two scores in the same model decreases the loss of information caused by differences in 
cut-offs. There was no significant co-linearity between our variables (All R values <0.2).  
We tested our model in the training cohort in each of the three categories of patients 
defined by the site of infection acquisition (community, hospital, or ICU) (Figure 2). In the 
overall training cohort, the final model exhibited good calibration (Hosmer-Lemeshow [HL] 
chi-square, 8.6; p>0.38) and good discrimination (AUC-ROC curve, 0.82). When we confined 
the analysis to the 573 episodes of community-acquired severe sepsis, the final model showed 
good calibration (HL chi-square, 8.0; p>0.43) and discrimination (AUC-ROC curve, 0.87). 
Validity was satisfactory in the analyses of hospital-acquired and ICU-acquired episodes, with 
HL chi-square p values greater than 0.05 (0.74 and 0.15, respectively) and AUC-ROC curve 
values of 0.80 in both groups. 
We also evaluated model accuracy for the 1458 first severe sepsis episodes in the 
training group (n=1458 patients) versus all subsequent episodes (n=258, including 56 after 
community-acquired severe sepsis, 96 after hospital-acquired severe sepsis, and 106 after 
ICU-acquired severe sepsis; Figure 1). AUC was 0.82 for first episodes and 0.82 for 
subsequent episodes. The difference was not significant according to the Hanley and McNeil 
test [19]. Moreover, calibration was satisfactory for both groups (HL chi square p>0.10).  
Interestingly, model accuracy was similar for severe sepsis at ICU admission (n=586, 
AUC=0.85) and later in the ICU stay (days 2-4: n=670, AUC=0.82; days 5-7: n=133, 
AUC=0.80; days 8-14: n=200, AUC=0.80; and days 15-28: n=127, AUC=0.80). Furthermore, 
multiple-site infection was not associated with the rank of severe sepsis episode and therefore 
did not correlate with the number of episodes (p=0.87 by Fisher exact test). 
Performance was slightly lower in the validation cohort (Figure 3). The final model 
used on all episodes of severe sepsis showed good calibration (HL chi-square 15.3, p=0.06) 
and good discrimination (AUC-ROC curve, 0.76). Results for community- and hospital-
acquired infections were satisfactory, with AUC-ROC curve values of 0.80 and 0.79, 
respectively, and with HL chi-square p values greater than 0.05 in both groups (0.35 and 0.06, 
respectively). Prediction of early death after ICU-acquired severe sepsis was less accurate, 
with an AUC-ROC curve of 0.70 but an HL chi-square p value of 0.02. These data are similar 
to with those obtained from calibration curves [See Additional Data File 1, Figure 1]. 
We also evaluated model performance at different times of the total study period. To 
this end, we considered three subperiods: 1997-2000, 2001-2004, and after 2004. Results 
were similar for these three periods in terms of discrimination and calibration (AUC=0.802, 
HL chi-square=10.8 for the first period; 0.832 and 4.8 for the second period; and 0.832 and 
11.0 for the last period). 
Moreover, we compared our model to daily severity scores. APACHE II, MPM II0, and 
SAPS II scores were significantly less accurate than our model, with AUCs of 0.73, 0.66, and 
0.72, respectively (<10-4 in all cases), and poor calibration (HL chi-square P values of 0.03, 
<10-4, and 0.02, respectively) (Figure 4). 
Discussion: 
We found that predicting death within 14 days after the onset of severe sepsis during 
the first 28 ICU days was feasible in patients with 0 to 3 previous episodes of severe sepsis. 
By adjusting for confounders, we were able to build a predictive model in a training cohort 
that performed well in the validation cohort. If used in randomised trials, this prognostic 
model might help to include patients with similar disease severity and to improve adjustment 
for confounders. 
We chose to study short-term mortality, despite the current trend among researchers to 
focus on long-term mortality [20-22]. Most studies of sepsis used 28-day all-cause mortality 
as the primary end-point. However, life-limiting disease is a common risk factor for sepsis 
and may cause death shortly after successful treatment of the septic episode. Early morbidity 
associated with sepsis is dominated by the side effects of life-supporting interventions (e.g., 
mechanical ventilation, dialysis, and vasoactive agents), whereas delayed morbidity (e.g., 
neuromuscular weakness, cognitive dysfunction, and neuropsychiatric sequelae) is chiefly 
related to prolonged ICU management. Sepsis is an acute event, and its main manifestation, 
acute organ dysfunction, does not seem associated with long-term mortality in patients who 
survive the original insults [22]. Furthermore, many studies failed to adjust appropriately for 
treatment-limitation decisions such as DNR given early (<2 days) or later during the ICU 
stay. Underlying illness is the main reason for DNR orders, which are taken in up to half the 
patients who die in the ICU [23]. Moreover, treatment-limitation decisions were found to be 
independently associated with ICU death [24].  
Severe infections per se are associated with a decrease in life expectancy. In a study 
that included controls from the general population, sepsis not only caused acute mortality, but 
also increased the risk of death for up to 5 years after the septic episode, even after adjustment 
for pre-existing co-morbidities [25]. The risk of delayed death during the first year was 
associated with the severity of the septic episode [25]. Several other studies showed that 
mortality and morbidity remained increased for several years among hospital survivors of 
infection and sepsis [26-30]. However, there is a two-way relationship between acute and 
chronic illnesses. Chronic disease increases the risk of infection and severe sepsis, and 
survivors of severe sepsis may experience an increase in their burden of chronic disease, 
which in turn may further elevate the risk for subsequent acute illnesses, thereby initiating a 
spiral of events that eventually causes death [22]. Therefore, a reasonable hypothesis is that 
early mortality (e.g., within 14 days) is ascribable to the severity of acute severe sepsis [31, 
32] and to the effectiveness of treatment, rather than to underlying chronic illnesses, provided 
patients with treatment-limitation decisions are excluded, as done in our study. Short-term 
survival may need to be viewed as a surrogate measure, as it is desirable only when followed 
by long-term survival with an acceptable quality of life. On the other hand, focusing on very 
long-term mortality, which is extremely relevant to healthcare-cost issues, may mask 
beneficial effects of drugs used to treat sepsis if the patient dies later on as a result of an 
underlying chronic illness associated with a risk of sepsis [22]. High death rates due to 
underlying diseases may explain why many therapeutic trials in patients with severe sepsis 
failed to detect benefits related to the experimental treatments. Although emphasis is often put 
on the α risk of false-positive results, the β risk of missing true effects as a result of 
inadequate statistical power is just as important for the overall population, as false-negative 
results deprive patients of effective treatments. Therefore, when designing large trials of 
treatments for severe sepsis, it may be appropriate to select candidate treatments in 
preliminary trials that use short-term mortality as the primary endpoint. 
We found that mortality from severe sepsis could be predicted based on variables 
associated with the PIRO concept [33] (P: co-morbidities, McCabe; I: multiple-site infection, 
number of severe sepsis episodes; and R and O: organ dysfunction and vasoactive drug use). 
These findings are in accordance with a very recent report of a PIRO-based score designed to 
predict 28-day mortality from sepsis, thus focusing on a nearer time horizon than many recent 
studies evaluating longer term outcome (e.g.> 3 months) [20]. Studies of pneumonia already 
used 14-day mortality as the primary outcome of interest, to separate the impact of pneumonia 
from that of co-morbidities or other factors [31, 32]. 
Our study has several limitations. First, the location of the patient before hospital 
admission was not recorded in the early years of our database. Patients who are chronically in 
contact with healthcare systems on an outpatient or day-hospital basis (e.g., for chronic 
dialysis or other chronic treatments) are at risk for severe infection with resistant strains, 
although they are not admitted [34]. We have been recording this variable since April 2000 
and have found that fewer than 5% of patients directly admitted to the database ICUs are 
recipients of chronic hospital-based outpatient care. Moreover, hospital-acquired infection (in 
patients transferred to the ICU from other wards) was diagnosed in more than half our patients 
and was not associated with 14-day mortality (Table 1, p=0.85). Second, calibration as 
assessed using the Hosmer-Lemeshow goodness-of-fit was unsatisfactory (HL chi-square P 
value <0.05), although discrimination remained good (AUC-ROC= 0.7 [0.65-0.75]) for ICU-
acquired severe sepsis in the validation dataset (Figure 3). Third, our model was developed in 
a single type of healthcare system. External validation studies are needed before the model 
can be used in countries that have different healthcare systems from the one in France. 
Finally, it should be borne in mind that the relevance of 14-day mortality to long-term 
treatment benefits remains to be evaluated. However our model was clearly superior to widely 
used models (figure 4) and may prove helpful for designing and analyzing future trials. 
Conclusions:  
We developed a model for predicting death within 14 days after the diagnosis of the 
first, second, third, or fourth episode of severe sepsis occurring within 28 days after ICU 
admission. The model is based on a few readily available variables. It may help to evaluate 
the effectiveness of new drugs or treatment strategies in reversing severe sepsis. In contrast, 
long-term mortality may be a better marker for the efficacy of treatments directed against 
sepsis, as recovery from sepsis may be followed by death due to underlying illnesses. 
 
Key messages: 
• We developed a model for predicting short-term (14 days) mortality after each episode 
of severe sepsis, using readily available variables. The model proved very accurate for 
predicting mortality after one to four severe sepsis episodes in the ICU. 
• The model was accurate for community, hospital, and ICU-acquired episodes of 
severe sepsis, in both the training and the validation cohort (n=2737 episodes overall). 
• This prediction model is designed to predict death related directly to severe sepsis, as 
opposed to co-morbidities or DNR decisions, which contribute substantially to longer-
term mortality rates. 
• Our model may help to evaluate the effectiveness of a drug or strategy in severe 
sepsis, by avoiding Type II errors stemming from inadequate statistical power to 
detect therapeutic effects despite the substantial mortality due to co-morbidities, 
treatment-limitation decisions and DNR orders. 
• In future studies, our model may help to select uniform patient groups for inclusion in 
clinical trials and to improve adjustment for confounders. 
 
Abbreviations: ICU; intensive care unit, SAPS II score;  Simplified Acute Physiology Score, 
LOD score; Logistic Organ Dysfunction score, MPM II0 score; Mortality Probability models 
II0 score, APACHE II score; Acute Physiologic and Chronic Health Evaluation II score, 
COPD; chronic obstructive pulmonary disease, DNR; do not resuscitate order, ROC; receiver-
operating characteristics, AUC; area under the curve, OR; odds ratio, HL;  Hosmer-Lemeshow 
chi-square. 
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Figure legends 
 
Figure 1. Flow diagram of the 2268 patients with severe sepsis who formed the basis for the 
study and who were identified among the 7719 patients included in the Outcomerea® 
Database. Data are expressed as counts (number of episodes of severe sepsis) or percentages. 
Mortality is defined as death within 14 days after the diagnosis of severe sepsis. SIRS, 
systemic inflammatory response syndrome; Sepsis, SIRS with infection; ICU, intensive care 
unit; community-acquired infection, infection manifesting before or within 48 hours after 
hospital admission; hospital-acquired infection, infection manifesting at least 48 hours after 
hospital admission but before ICU admission; ICU-acquired infection, infection manifesting 
at least 48 hours after ICU admission. N: number of patients (number of episode). : 
Mortality (percentage %) 
Figure 2. Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) 
chi-square test results for the prediction model in the training cohort (n=1458 patients, 1716 
episodes), according to the type of severe sepsis (community-, hospital-, or ICU-acquired). 
Dashed curves represent 95% confidence intervals (95%CI) of the area under the curve 
(AUC) of the ROC curve.  
Figure 3. Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) 
chi-square test results of the prediction model in the validation cohort (n=810, 
episodes=1021), according to the day of severe sepsis. Dashed curves represent 95% 
confidence intervals (95%CI) of the area under the curve (AUC) of the ROC curve. 
Figure 4: Comparison of our prediction model with other, widely used models. The final 
study model (blue line) used on all episodes of severe sepsis showed good calibration (HL 
chi-square 15.3, p=0.06) and good discrimination (AUC-ROC curve, 0.76). APACHE II, 
MPM0 II and SAPS II scores were significantly less accurate than our model, with AUCs of 
0.73, 0.66, and 0.72, respectively (10-4 in all cases), and poor calibration (HL chi-square p 
values of 0.03, <10-4, and 0.02, respectively). 
Table 1. Baseline characteristics at ICU admission of 1458 patients with severe sepsis  
Variables at ICU admission 
 Patients alive 14 days after 
severe sepsis  
(n=1177) 
Patients who died within 14 
days after severe sepsis 
(n=281) 
p value 
Chi2 test 
Male gender  725 (61.6) 188 (66.9) 0.10 
Age 66 [52- 76] 69 [56-77] <10-2 
Transfer from ward 600 (51) 145 (51.6) 0.85 
SAPS II 41 [31-53] 59 [44- 5] <10-4 
LOD 4 [2-6] 7 [5-10] <10-4 
SOFA 6 [4-8] 9[7-12] <10-4 
APACHE II  18 [14-22] 24 [20-29] <10-4 
Admission category                                 (4 missing) 
     Medical 845 (71.8) 207 (73.7) 0.53 
     Emergency surgery 230 (19.5) 52 (18.5) 0.69 
     Scheduled surgery 98 (8.3) 22 (7.8) 0.79 
McCabe score (4 missing) (1 missing) <10-4 
    1 694 (59) 99 (35.2)  
    2 397 (33.7) 134 (47.7)  
    3 82 (7) 47 (16.7)   
Main symptom at admission 
     Multiple organ failure 39 (3.3) 29 (10.3) <10-2 
     Shock 367 (31.2) 105 (37.4) 0.05 
     Acute respiratory failure 384 (32.6) 73 (26) 0.03 
     Exacerbation of COPD 61 (5.2) 12 (4.3) 0.53 
     Acute renal failure 50 (4.2) 10 (3.6) 0.60 
     Coma 140 (11.9) 39 (13.9) 0.36 
     Trauma 12 (1) 1 (0.4) 0.29 
     Continuous monitoring 97 (8.2) 7 (2.5) <10-2 
     Scheduled surgery 27 (2.3) 5 (1.8) 0.60 
History of immunodeficiency 
     Haematological malignancy 78 (6.6) 29 (10.3) 0.03 
     Metastatic cancer 59 (5) 25 (8.9) 0.01 
     AIDS 41 (3.5) 16 (5.7) 0.09 
     Chemotherapy 90 (7.6) 32 (11.4) 0.04 
     Steroid therapy 68 (5.8) 28 (10) 0.01 
     Neutropenia 42 (3.6) 13 (4.6) 0.40 
Co-morbidities (Knaus definitions)  
     Chronic pulmonary failure 198 (16.8) 57 (20.3) 0.17 
     Immunodeficiency 187 (15.9) 67 (23.8) <10-2 
     Chronic heart failure 142 (12.1) 48 (17.1) 0.02 
     Chronic hepatic failure 52 (4.4) 35 (12.5) <10-2 
     Chronic renal failure 29 (2.5) 15 (5.3) 0.01 
     Exactly one chronic illness 405 (34.4) 136 (48.4) <10-4 
     Two or more chronic illnesses 94 (8.0) 42 (15.0) <10-3 
     Diabetes mellitus 88 (7.5) 26 (9.3) 0.32 
ICU stay (days) 11 [6-23] 8 [4-12] <10-4 
Hospital stay (days) 33 [19-57] 11 [6-17] <10-4 
Type of acquisition of first episode of severe sepsis 0.46 
    Community-acquired 471 (40) 102 (36.3)  
    Hospital-acquired 454 (38.7) 112 (39.9)  
    ICU-acquired 252 (21.4) 67 (23.8)   
 
ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; AIDS, acquired immunodeficiency 
syndrome  
Table 2. Baseline characteristics of the 1458 patients in the training cohort, on the first 
day of severe sepsis 
Variables on the day with severe sepsis 
 
 
Number of episodes of 
severe sepsis in patients 
alive 14 days after severe 
sepsis (n=1367) 
Number of episodes of 
severe sepsis in patients who 
died within 14 days after 
severe sepsis (n=349) 
p value 
Chi2 
test 
Organ dysfunctions based on the LOD score 
   Neurological 386 (28.2) 155 (44.4) <10-4 
   Cardiovascular 590 (43.2) 237 (67.9) <10-4 
   Renal 1052 (77) 316 (90.5) <10-4 
   Haematological 174 (12.7) 73 (20.9) <10-4 
   Hepatic 199 (14.6) 98 (28.1) <10-4 
Procedures      
   Vasoactive and/or inotropic drugs 681 (49.8) 249 (71.3) <10-4 
   Mechanical ventilation 943 (69) 299 (85.7) <10-4 
   Arterial catheter 367 (26.8) 142 (40.7) <10-4 
   Central catheter 769 (56.3) 266 (76.2) <10-4 
   Swan catheter 70 (5.1) 48 (13.8) <10-4 
   At least one intravascular catheter  817 (59.8) 278 (79.7) <10-4 
   Urinary tract catheter 1081 (79.1) 311 (89.1) <10-4 
Treatments on the first day of severe sepsis 
   Corticosteroid 350 (25.6) 107 (30.7) 0.06 
   Antibiotic 1190 (87.1) 294 (84.2) 0.17 
   Extra-renal replacement therapy 68 (5) 51 (14.6) <10-4 
   Early effective antibiotic therapy 1036 (75.8) 250 (71.6) 0.11 
Micro-organism 
   Escherichia coli 170 (12.4) 60 (17.2) 0.02 
   Streptococcus pneumoniae 104 (7.6) 22 (6.3) 0.41 
  Pseudomonas species 153 (11.2) 52 (14.9) 0.06 
  Staphylococcus aureus 173 (12.7) 44 (12.6) 0.98 
     Methicillin-resistant S. aureus 53 (3.9) 23 (6.6) 0.03 
     Methicillin-susceptible S. aureus 120 (8.8) 21 (6) 0.09 
   Candida species 42 (3.1) 20 (5.7) 0.02 
   Enterococcus species 124 (9.1) 41 (11.7) 0.13 
   Acinetobacter baumannii 14 (1) 3 (0.9) 0.78 
   Other Gram-positive 110 (8) 22 (6.3) 0.27 
   Multiple organisms 162 (11.9) 37 (10.6) 0.52 
   Resistant organisms 95 (6.9) 33 (9.5) 0.05 
   Unknown 581 (42.5) 124 (35.5) 0.02 
Site of infection 
   Pneumonia 668 (48.9) 171 (49) 0.96 
   Peritonitis 187 (13.7) 55 (15.8) 0.32 
   Urinary tract 186 (13.6) 52 (14.9) 0.53 
   Exacerbation of COPD 127 (9.3) 33 (9.5) 0.92 
   All forms of bacteraemia 425 (31.1) 134 (38.4) 0.01 
        Primary bacteraemia 129 (9.4) 34 (9.7) 0.86 
        Associated bacteraemia 296 (21.7) 100 (28.7) <10-2 
   Catheter-related infection 86 (6.3) 22 (6.3) 0.99 
   Miscellaneous infection sites 136 (9.9) 39 (11.2) 0.50 
   Multiple infection sites 156 (11.4) 59 (16.9) <10-2 
Rank of severe sepsis episode                                                                                                                            0.01 
   One 1177 (86.1) 281 (80.5)  
   Two 152 (11.1) 49 (14)  
   Three 30 (2.2) 17 (4.9)  
   Four 8 (0.6) 2 (0.6)   
 Table 3. Generalized linear model obtained in our study 
Main effect 
Beta 
estimate Odds ratio p value 
        
Intercept -4.9419 - <10-4 
Parameters on the day of severe sepsis 
LOD (per point) 0.1951 1.22 [1.16-1.27] <10-4 
Septic shock 0.3335 1.40 [1.08-1.81] 0.01 
First episode of severe sepsis - - - 
Second episode of severe sepsis 0.2304 1.26 [0.96-1.66] 0.10 
Third or fourth episode of severe sepsis 0.9719 2.64 [1.71-4.08] <10-4 
Multiple sites of infection 0.3734 1.45 [1.04-2.03] 0.03 
Variables at ICU admission 
SAPS (per point) 0.0244 1.02 [1.01-1.03] <10-4 
Fatal illness by McCabe Score(score 2 or 3) 0.6749 1.96 [1.43-2.70] <10-4 
No chronic illness - - - 
Exactly one chronic illness 0.5592 1.75 [1.25-2.45] 0.001 
Two or more chronic illnesses 0.8084 2.24 [1.39-3.62] 0.001 
 
 
The area under the Receiver-Operating Characteristics curve was 0.822 and the Hosmer-
Lemeshow chi-square test was 8.6 (p>0.05, 8 df), indicating good discrimination and good 
calibration of the final model in the training cohort. The following variables were tested in the 
generalized linear model: LOD, SOFA, septic shock, high-dose vasoactive drugs (epinephrine 
and/or norepinephrine >0.1 γ/kg/min), multiple sites of infection, SAPS II score, age, number 
of chronic organ failures (none, exactly one, or two or more), arterial, central venous line or 
Swan-Ganz catheter, diagnosis at ICU admission, year of admission, centre, early effective 
antibiotic therapy, corticosteroid therapy, male gender, main symptom (multiple organ failure 
and cardiogenic shock), metastatic cancer, mechanical ventilation, urinary tract catheter, 
sedation, extrarenal replacement therapy, McCabe score, nature of the microorganism (E. coli, 
Candida spp and methicillin-susceptible S. aureus), infection site and LOD increase from the 
day before to the day of severe sepsis diagnosis. 
To calculate the predicted risk of death for each patient: 
- compute the logit : logit = sum (‘Beta estimate’ multiplied by value of corresponding parameter) 
- compute the probability, using the logit : p =( exp (logit)) divided by (1+exp(logit)) 
Description of additional data files (Word): 
The following additional data are available with the online version of this paper: 
Additional Data File 1 represents a figure showing calibration curves of both training and 
validation cohorts. 
 
Additional Data File 2 is a List of the Members of the Outcomerea Study Group: Scientific 
committee, Biostatistical and informatics expertise, Investigators and Clinical Research 
Assistants 
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